Anlotinib for Esophageal Cancer (AFEC)

Anyang Tumor Hospital

Status: Enrolling

Conditions: Esophageal Cancer

Treatments: Drug: Anlotinib

Study type: Observational

Funder types: Other

Identifiers

NCT04966611

AZLL022020001200116

Details and patient eligibility

About

The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the treatment experience of a wide range of people.

Enrollment: 200 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age: ≥ 18 years old, male or female;
2. Patients with esophageal cancer were diagnosed;
3. Patients assessed by doctors to benefit from single or combined treatment of arotinib;
4. Patients volunteered to join the project.

Exclusion criteria

None